Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity

Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity: an Open Randomized Controlled Feasibility Study

This study aims to evaluate the feasibility of an open randomized controlled study which would assess the proportion patients with obesity who will have a favorable pharmacodynamic parameter (i.e. fT> 100% MIC) after 24 hours of piperacillin-tazobactam administered as a prolonged intermittent infusion compared to a standard infusion.

Inclusion Criteria:

• Adults (18 years and older)
• Patients hospitalized at Hôpital Charles-Le Moyne
• Obesity (as defined by a body mass index of ≥ 30 kg/m^2)
• Piperacillin-tazobactam prescription initiated within last 24 hours
• Planned duration of piperacillin-tazobactam of 24 hours or more

Exclusion Criteria:

• Documented allergy to beta-lactams of the penicillin class
• Patients with renal replacement therapy (hemodialysis, peritoneal dialysis, continuous venovenous hemodiafiltration)
• Pregnancy
• History of seizures or epilepsy, active seizures or epilepsy treated with antiepileptic drug therapy
• Patients on prolonged intermittent infusion or continuous infusion of piperacillin-tazobactam before randomization